Orphacol (Cholic Acid)

Cholic acid integrates into the body's enterohepatic circulation after oral intake. It replenishes the bile acid pool, enhances micelle formation, and promotes the emulsification of dietary lipids, thereby facilitating enzymatic breakdown and absorption of fats in the small intestine.

The dosage of Orphacol is individualized and set by the prescribing healthcare professional based on the patient’s condition, age, weight, and response to therapy. Specific dosing regimens are not provided here and should be obtained from a qualified prescriber.

Safety data for cholic acid in pregnancy and lactation are limited. Use of Orphacol during pregnancy or while breastfeeding should only occur after a risk‑benefit assessment by a qualified healthcare provider. The prescriber will determine if the potential benefits outweigh any possible risks.

To order Orphacol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any required import documentation.

Orphacol provides cholic acid, a primary bile acid, whereas alternatives such as ursodeoxycholic acid (UDCA) are secondary bile acids with different therapeutic profiles. Cholic acid is typically used for primary bile acid deficiency, while UDCA is often employed for cholestatic liver diseases like primary biliary cholangitis. The choice depends on the specific clinical indication and physician judgment.

Store Orphacol at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Orphacol is taken orally, usually with water. The exact timing (e.g., with meals or on an empty stomach) and frequency are determined by the prescribing clinician based on the patient’s therapeutic needs and tolerance.

Serious risks include severe allergic reactions such as anaphylaxis, marked liver enzyme elevations leading to jaundice, acute pancreatitis, and worsening of cholestasis in susceptible individuals. Patients should be monitored for signs of liver dysfunction, abdominal pain, or hypersensitivity and seek medical attention promptly if they occur.

Orphacol should be avoided in individuals with known hypersensitivity to cholic acid or any excipients in the formulation. Patients with severe liver failure, uncontrolled cholestasis, or those taking medications that have major contraindicated interactions (e.g., certain bile‑acid sequestrants) should not use this product without specialist guidance.